Pandemic Clinical Trials Need More Top-Down Control, Gottlieb Says
Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.
You may also be interested in...
One such trial is being developed, but was needed early in the pandemic to answer many lingering questions about potential COVID-19 treatments.
Decentralized and remote flexibilities should stay, Gottlieb says, but so should e-detailing efforts.
US government’s $450m manufacturing commitment for Regeneron’s antibody cocktail and Gilead’s price for remdesivir drive lower expectations on pricing for the antibody treatments, especially since it seems likely there could be several competing products.